Clinical Trial

Analysis of Prevalence and Risk Factors Associated With Gastroesophageal Reflux Disease and Esophagitis After Peroral Endoscopic Myotomy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 18, 2021 (before its estimated June 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Achalasia is an uncommon disorder that results from the degeneration of ganglion cells of the myenteric plexus in the lower esophageal wall. Peroral endoscopic myotomy (POEM) is a minimally invasive procedure capable of overcoming limitations of achalasia treatments. This study aimed to: 1) identify the prevalence of reflux esophagitis and asymptomatic GERD in patients who underwent POEM, and 2) evaluate patient and intraprocedural variables associated with post-POEM GERD.
Trial Details
NCT Number NCT05080634
Lead Sponsor Maria Sklodowska-Curie National Research Institute of Oncology
Conditions Achalasia, GERD
Enrollment 100 participants
Start Date 2021-06-01
Primary Completion 2024-06-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2021-10-18